Prospective evaluation of frequencies of febrile neutropenia or infectious complications in a homogeneous population of patients with peripheral T cell lymphoma
Age
19–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
1. Treatment naive peripheral T cell lymphoma
Subtypes are as followings:
Anaplastic large cell lymphoma angioimmunoblastic T cell lymphoma Peripheral T cell lymphoma-NOS Enteropathy-associated T cell lymphoma Hepatosplenic T-cell lymphoma Subcutaneous panniculitis-like T-cell lymphoma Primary cutaneous gamma-delta T-cell lymphoma Primary cutaneous CD8+ aggressive epidermotropic lymphoma
2. Scheduled to receive chemotherapy of curative intent
3. 19 years old or over
4. Expected survival is more than 6 months
5. Informed consent
You may not be if
1. Other histology than those described above
* Extranodal NK/T cell lymphoma
* Other than peripheral T cell lymphoma
2. Other combined malignancy
3. Previous history of chemotherapy or radiation therapy
4. No informed consent
Clareo Health | Cohort of Peripheral T Cell Lymphoma
